Here's Why Pacific Biosciences of California Is Getting Hammered Today
Shares of DNA-sequencing pioneer Pacific Biosciences of California (NASDAQ: PACB) fell as much as 21.6% this morning after the company missed third-quarter revenue estimates by a mile. While management pointed to several bright lights on the horizon, the stock is still down about 20.6% as of 12:37 p.m. EDT on Friday.
Third-quarter total revenue came in at $23.5 million. That was $1.6 million than third-quarter revenue last year, and $5.1 million less than Wall Street was expecting. Adjusting for contract revenue from Roche that PacBio will no longer receive following last year's fallout turns the year-to-year loss into a slight gain, but that didn't stop investors from worrying about the company's ability to eventually turn a profit. The third-quarter loss widened to $22.0 million from $17.5 million last year.
Image source: Getty Images.
Source: Fool.com
Pacific Biosciences of California Inc. Stock
Our community is currently high on Pacific Biosciences of California Inc. with 10 Buy predictions and 5 Sell predictions.
Based on the current price of 1.75 € the target price of 10 € shows a potential of 472.08% for Pacific Biosciences of California Inc. which would more than double the current price.
